This suggests two main things; first, that SGLT2 inhibitors act on bone metabolism through additional pathways, which are still to be elucidated, and second, that several research variables should be included, such as renal and cardiac function, sarcopenia and low body weight, as well as advanced age. Here, SLC5A2 is linked to sarcopenia.